Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Protective effect of tolvaptan against cyclophosphamide-induced nephrotoxicity in rat models.
Pharmacol Res Perspect. 2020 Oct;8(5):e00659. doi: 10.1002/prp2.659.
Pharmacol Res Perspect. 2020.
PMID: 32996719
Free PMC article.
Nebivolol protects against cyclophosphamide-induced nephrotoxicity through modulation of oxidative stress, inflammation, and apoptosis.
Wanas H, El-Shabrawy M, Mishriki A, Attia H, Emam M, Aboulhoda BE.
Wanas H, et al. Among authors: mishriki a.
Clin Exp Pharmacol Physiol. 2021 May;48(5):811-819. doi: 10.1111/1440-1681.13481. Epub 2021 Feb 15.
Clin Exp Pharmacol Physiol. 2021.
PMID: 33590494
Item in Clipboard
Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol.
Garg DC, Jallad NS, Mishriki A, Chalavarya G, Kraml M, Fencik M, Weidler DJ.
Garg DC, et al. Among authors: mishriki a.
J Clin Pharmacol. 1987 May-Jun;27(5):390-6. doi: 10.1002/j.1552-4604.1987.tb03036.x.
J Clin Pharmacol. 1987.
PMID: 3693583
Clinical Trial.
Item in Clipboard
Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
Shabana MF, Mishriki AA, Issac MS, Bakhoum SW.
Shabana MF, et al. Among authors: mishriki aa.
Mol Diagn Ther. 2013 Oct;17(5):299-309. doi: 10.1007/s40291-013-0038-3.
Mol Diagn Ther. 2013.
PMID: 23677857
Item in Clipboard
Long-acting propranolol (Inderal LA): pharmacokinetics, pharmacodynamics and therapeutic use.
Mishriki AA, Weidler DJ.
Mishriki AA, et al.
Pharmacotherapy. 1983 Nov-Dec;3(6):334-41. doi: 10.1002/j.1875-9114.1983.tb03294.x.
Pharmacotherapy. 1983.
PMID: 6361703
Review.
Item in Clipboard
Global multi-stakeholder endorsement of the MAFLD definition.
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease.
Méndez-Sánchez N, et al.
Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3.
Lancet Gastroenterol Hepatol. 2022.
PMID: 35248211
Free article.
No abstract available.
Item in Clipboard
Cite
Cite